Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833416 | 1.00 | CA2 (0.61) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL14199406 | 1.00 | CA2 (0.61) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL2305466 | 1.00 | CA2 (0.61) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL14178477 | 1.00 | CA2 (0.61) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL15685476 | 1.00 | CA2 (0.61) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL20345392 | 0.92 | CA2 (0.50) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL18121292 | 0.92 | CA2 (0.50) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL18091409 | 0.92 | CA2 (0.50) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL6286314 | 0.88 | HPGD (0.64) | CA2CA1CA9ALDH1A1HPGD | |
| SCHEMBL7148239 | 0.88 | HPGD (0.64) | CA2CA1CA9ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | disclosed |
| EP-1797192-A1 | MODIFIED PROTEINS | Novo Nordisk Health Care AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035057-A1 | MODIFIED PROTEINS | NOVO NORDISK HEALTH CARE AG (DK) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | PTMS, DNPEP, STT3A | CA2 4529/4885CA1 3490/4885CA9 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.